ANI PHARMACEUTICALS, INC Contract with Customer, Performance Obligation Satisfied in Previous Period
ANI PHARMACEUTICALS, INC (ANIP) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $2.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-02-27
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-12-31 was $800.00K.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-09-30 was -$700.00K, a 138.89% decline year-over-year.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-06-30 was -$1.30M, a 192.86% decline year-over-year.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-03-31 was $3.30M, a 3200.00% increase year-over-year.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $2.10M, a 30.00% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $3.00M, a 26.83% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $4.10M, a 86.36% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $2.20M, a 77.78% decline from fiscal 2021.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month as first filed | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month as first filed | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $100.00K derived: sum of 2 quarters · filed 2026-02-27 | -$1.20M derived: sum of 3 quarters · filed 2026-02-27 | $2.10M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | -$700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$2.00M derived: sum of 2 quarters · filed 2025-11-07 | $1.30M 10-Q · filed 2025-11-07 | $1.00M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2025-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $2.00M 10-Q · filed 2025-08-08 | $1.70M derived: sum of 3 quarters · filed 2025-08-08 | $3.50M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2025-03-31 | $3.30M 10-Q · filed 2025-05-09 | $3.00M derived: sum of 2 quarters · filed 2025-05-09 | $4.80M derived: sum of 3 quarters · filed 2025-11-07 | $6.20M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.50M derived: sum of 2 quarters · filed 2025-11-07 | $2.90M derived: sum of 3 quarters · filed 2025-11-07 | $3.00M 10-K · filed 2025-02-28 | ||
| 2024-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $3.20M derived: sum of 2 quarters · filed 2025-11-07 | $3.30M 10-Q · filed 2025-11-07 | -$1.10M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.50M 10-Q · filed 2025-08-08 | -$2.90M derived: sum of 3 quarters · filed 2025-08-08 | $600.00K derived: sum of 4 quarters · filed 2025-08-08 | ||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-09 | -$4.30M derived: sum of 2 quarters · filed 2025-05-09 | -$800.00K derived: sum of 3 quarters · filed 2025-05-09 | -$900.00K derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$900.00K derived: sum of 2 quarters · filed 2024-11-08 | -$1.00M derived: sum of 3 quarters · filed 2024-11-08 | $4.10M 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $3.40M derived: sum of 2 quarters · filed 2024-11-08 | $8.50M 10-Q · filed 2024-11-08 | $8.10M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $5.00M 10-Q · filed 2024-08-06 | $4.60M derived: sum of 3 quarters · filed 2024-08-06 | $3.50M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $5.10M 10-Q · filed 2024-05-10 | $4.70M derived: sum of 2 quarters · filed 2024-05-10 | $3.60M derived: sum of 3 quarters · filed 2024-05-10 | $6.00M derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$1.50M derived: sum of 2 quarters · filed 2023-11-08 | $900.00K derived: sum of 3 quarters · filed 2023-11-08 | $2.20M 10-K · filed 2023-03-09 | ||
| 2022-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.30M derived: sum of 2 quarters · filed 2023-11-08 | $2.60M 10-Q · filed 2023-11-08 | $3.80M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.70M 10-Q · filed 2023-08-09 | $4.90M derived: sum of 3 quarters · filed 2023-08-09 | $3.30M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-08 | $2.50M derived: sum of 2 quarters · filed 2023-05-08 | $900.00K derived: sum of 3 quarters · filed 2023-05-08 | $500.00K derived: sum of 4 quarters · filed 2023-05-08 | ||
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$400.00K derived: sum of 2 quarters · filed 2022-11-09 | -$800.00K derived: sum of 3 quarters · filed 2022-11-09 | $9.90M 10-K · filed 2022-03-15 | ||
| 2021-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$2.00M derived: sum of 2 quarters · filed 2022-11-09 | $8.70M 10-Q · filed 2022-11-09 | $11.00M 10-Q · filed 2021-11-01 | $27.30M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $10.30M 10-Q · filed 2022-08-08 | $28.90M derived: sum of 3 quarters · filed 2022-08-08 | $25.90M derived: sum of 4 quarters · filed 2022-08-08 | ||
| 2021-03-31 | $10.70M 10-Q · filed 2022-05-10 | $29.30M derived: sum of 2 quarters · filed 2022-05-10 | $26.30M derived: sum of 3 quarters · filed 2022-05-10 | $23.00M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $15.60M derived: sum of 2 quarters · filed 2021-11-01 | $12.30M derived: sum of 3 quarters · filed 2021-11-01 | $9.90M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$6.30M derived: sum of 2 quarters · filed 2021-11-01 | -$8.70M 10-Q · filed 2021-11-01 | $8.70M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | -$3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$5.70M 10-Q · filed 2021-08-06 | $5.70M 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | -$2.40M 10-Q · filed 2021-05-07 | |||||
| 2019-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $6.50M 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $3.50M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |